Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
3 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
The most important strategy is global awareness of ILD as a potentially serious complication that may initially present with subtle signs. Patients and all care team members must not only be aware but remind others in the patient/family care circle. This needs to be reinforced regularly. The recogni...
Mednet Member
Medical Oncology · Vall d’Hebron Institute of Oncology
At the time being, we do not have specific strategies to mitigate the risk of developing ILD/pneumonitis while using T-DXd. In my opinion, we need prospective data to try to prevent this adverse event which has been reported in the range of 10.5% of patients. However, this event is not unique, and i...
Mednet Member
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Pulmonary toxicity of T-DXd may represent off-target toxicity, as other DXd-based ADCs, anti-Trop2 datopotamab deruxtecan, and the anti-HER3 patritumab deruxtecan are capable of inducing ILD. The impact of an increased understanding of T–DXd–related ILD will likely extend beyond breast oncology, giv...